Hartford insurer Aetna has entered into a value-based agreement with pharmaceutical company Merck for two type 2 diabetes medications, Januvia and Janumet.
Merck also becomes the first healthcare company to participate in AetnaCareSM, a personalized health and wellness initiative that provides members information, tools and support to take a proactive role in managing their own health.
The two companies have entered into a value-based contract that supports their objectives in helping adult patients with appropriate treatment access for type 2 diabetes. Under the pact, Merck’s rebates on Januvia and Janumet will be based in part on those products’ contributions to helping Aetna’s commercial members with type 2 diabetes achieve or maintain treatment objectives.
Dr. Harold L. Paz, executive vice president and chief medical officer for Aetna and Robert McMahon, president, U.S. Market, Global Human Health, at Merck, both hailed the focus on healthy outcomes.
Separately, the two companies are collaborating on AetnaCare, an approach that uses predictive analytics to identify target populations and proactively curate various health and wellness services as they are available to each member. The aim is to support treatment adherence and reinforce healthy lifestyle behaviors.
The program will initially target patients with diabetes and hypertension in Mid-Atlantic markets.
